Sidley represented Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, in its acquisition of Faeth Therapeutics Inc., a clinical-stage biotechnology company developing multi-node therapies targeting tumor metabolism and signaling.
Concurrent with the acquisition, Sidley also represented Sensei in its definitive agreement for the sale of Series B non-voting convertible preferred stock in a private placement expected to result in gross proceeds of approximately US$200 million.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.